Princeton Licenses Oncology Genes to Genome Therapeutics

Dec 17, 1998

Premium

WALTHAM, Mass.--Genome Therapeutics here announced that it acquired an exclusive license to proprietary genes regulated by the T53 tumor suppressor gene from Prince ton University. The agreement will enable Genome Therapeutics to develop proprietary targets within the p53 signal pathway that could lead to the identification of potential gene therapies and the development of new cancer treatments. Under terms of the agreement, Princeton will receive an undisclosed license fee and share in any product royalties created through future alliances.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Testing, Testing for Mutations

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

Hide, Nessie, Hide

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

Even More Variety

The New York Times writes about the appearance of mosaicism in healthy people.

This Week in PNAS

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.

Featured White Papers

Starlims Biorepository Solution Helps Fortune 200 Company Boost Efficiency, Cost Effectiveness, And Increase Sample Management By 25 Percent

ABBOTT Informatics STARLIMS Solution Helps Precision Diagnostics Achieve Compliance and Retain Customers

Meeting Modern Data Integrity and Compliance Requirements

Integrating Next Generation Sequencing Into Mainstream Laboratory Testing

Jun

05

Featured Webinar

Text Mining at Sanofi for Genotype-Phenotype Associations in Multiple Sclerosis

This webinar will discuss how Sanofi used literature mining to annotate the association of human leukocyte antigen (HLA) alleles with diseases and drug hypersensitivity as part of a multiple sclerosis (MS) biomarker discovery project.

Jun

12

Featured Webinar

Bridging the Gap Between Testing and Treatment in Precision Oncology

This webinar will highlight a comprehensive end-to-end solution for precision care in oncology, comprising sample acquisition through to sequencing and analysis, treatment recommendations, and follow-through.

Jun

14

Featured Webinar

Overcoming Challenges in Hematological Genomic Testing with Advanced AI

This webinar will discuss an effort underway at the University of North Carolina Medical Center's to overcome limitations in the hematological genomic testing workflow with artificial intelligence (AI) from Sophia Genetics.

Jun

21

Featured Webinar

Evaluation & Implementation of NGS Liquid Biopsy Assays

This webinar will provide a detailed look at how a genomics lab implemented next-generation sequencing (NGS) liquid biopsy assays into its in-house clinical research program.

Main menu